Physician profile
Anthony D Lowman
NPI 1083617880
$7,522.47
in general payments reported to CMS, 2019-2025
31 companies · $74.97 in 2025
The $74.97 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,875 · 2020: $781 · 2021: $2,160 · 2022: $1,518 · 2023: $1,079 · 2024: $34.09 · 2025: $74.97.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,188.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,870.84 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,092.48 | 2019-2023 | Xifaxan |
| Boston Scientific Corporation | $941.05 | 2019-2021 | |
| Janssen Biotech, INC. | $490.95 | 2019-2022 | |
| Gilead Sciences, INC. | $439.42 | 2019-2024 | |
| Covidien LP | $387.58 | 2019 | |
| Celgene Corporation | $314.70 | 2021-2023 | Zeposia |
| Qol Medical, LLC | $313.26 | 2021-2025 | Sucraid |
| Pfizer INC. | $254.13 | 2020-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $220.27 | 2019-2023 | Entyvio |
| Nestle Healthcare Nutrition INC. | $200.37 | 2020-2021 | |
| Ironwood Pharmaceuticals, INC | $178.16 | 2020-2023 | Linzess |
| Ferring Pharmaceuticals INC. | $139.68 | 2020-2023 | Rebyota |
| Daiichi Sankyo INC. | $94.70 | 2020-2025 | Injectafer |
| Amgen INC. | $69.99 | 2022-2023 | Amjevita, Avsola |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $58.76 | 2023 | |
| Braintree Laboratories, INC. | $55.02 | 2020-2022 | |
| Echosens North America, INC. | $53.83 | 2019 | |
| Merck Sharp & Dohme LLC | $46.26 | 2023 | Dificid |
| Fresenius Kabi USA, LLC | $38.79 | 2023 | Idacio |
| Intercept Pharmaceuticals, INC. | $38.32 | 2020-2021 | |
| Ucb, INC. | $33.98 | 2019-2020 | |
| Endogastric Solutions, INC | $31.76 | 2019 | |
| Redhill Biopharma INC. | $27.80 | 2021 | |
| Endo Pharmaceuticals INC. | $27.55 | 2019-2020 | |
| Alfasigma USA, INC. | $24.67 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $22.62 | 2021 | |
| Ethicon US, LLC | $16.75 | 2022 | |
| Alnylam Pharmaceuticals INC. | $13.49 | 2021 | |
| W. L. Gore & Associates, INC. | $12.86 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $12.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Lowman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.